Develops phage-based drug candidates for patients with antibiotic-resistant lung and bloodstream infections.
10-K for FY2025, filed Mar 25, 2026We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage…View ↗
Our first phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas…View ↗
In parallel to developing novel phage therapeutics that target chronic bacterial infections, we have an acute bacterial infection clinical…View ↗
We believe a key advantage of our phage manufacturing expertise is the purity profiles and the lot-to-lot consistency of our phage…View ↗
$4.9M
10-K for FY2025, filed Mar 25, 2026
$4.9M ↗No. It lost $173.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
$54.9MView ↗
8-K, filed Jul 20, 2026
On July 17, 2026, the Board of Directors (the “Board”) of Armata Pharmaceuticals, Inc. (the “Company”) promoted and appointed David House…View ↗
Growing. Revenue grew 10% in 4 years, from $4.5M in FY2021 to $4.9M in FY2025, about 2% a year.
Acute lung infections
The latest report adds a preclinical program for acute Pseudomonas lung infections; the older report described a chronic lung program and a complicated bloodstream-infection program.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 25, 2026Based on clinical findings with our intravenously administered S. aureus phage product candidate AP-SA02 (described below), and the…View ↗
Competes with BiomX, Adaptive Phage Therapeutics, Intralytix, Locus Biosciences, and TechnoPhage
10-K for FY2025, filed Mar 25, 2026The majority of phage companies are focused on aspects outside of human health such as agriculture, food, environmental, veterinary…View ↗
Loading...